Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gross Profit (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Gross Profit for 3 consecutive years, with $49.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 93.18% to $49.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $152.5 million, a 222.58% increase, with the full-year FY2025 number at $152.5 million, up 222.58% from a year prior.
  • Gross Profit was $49.9 million for Q4 2025 at Phathom Pharmaceuticals, up from $43.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $49.9 million in Q4 2025 to a low of $515000.0 in Q4 2023.
  • A 3-year average of $22.3 million and a median of $24.8 million in 2025 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: surged 4919.22% in 2024, then skyrocketed 93.18% in 2025.
  • Phathom Pharmaceuticals' Gross Profit stood at $515000.0 in 2023, then soared by 4919.22% to $25.8 million in 2024, then skyrocketed by 93.18% to $49.9 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Gross Profit are $49.9 million (Q4 2025), $43.3 million (Q3 2025), and $34.5 million (Q2 2025).